Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Mkt Cap
Market Capitalization
₹993Cr
Rev Gr TTM
Revenue Growth TTM
27.34%
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|
|
Growth YoY Revenue Growth YoY% | 9.4 | -10.3 | -42.0 | 80.4 | -7.4 | -5.2 | 67.0 | 58.1 | 43.7 | 74.4 | 37.0 | -12.2 |
| 86 | 72 | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 | 104 | 112 |
Operating Profit Operating ProfitCr |
| 18.3 | 13.3 | -24.5 | 25.4 | 5.5 | 1.0 | 19.8 | 34.0 | 26.4 | 20.7 | 20.5 | 18.2 |
Other Income Other IncomeCr | -8 | 2 | -6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 | 5 | 1 |
Interest Expense Interest ExpenseCr | 6 | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 3 |
Depreciation DepreciationCr | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 |
| -1 | 2 | -29 | 16 | 1 | -6 | 12 | 45 | 32 | 28 | 24 | 17 |
| 4 | 0 | 0 | 6 | 8 | 0 | 1 | 7 | -1 | 6 | 6 | 5 |
|
Growth YoY PAT Growth YoY% | -168.5 | 185.3 | -243.6 | 126.5 | -35.0 | -368.3 | 138.3 | 279.3 | 566.7 | 464.3 | 62.1 | -68.3 |
| -5.0 | 2.7 | -51.1 | 10.1 | -7.3 | -7.6 | 11.7 | 24.2 | 23.8 | 15.8 | 13.8 | 8.8 |
| -1.4 | 0.6 | -7.3 | 3.4 | -2.4 | -2.0 | 3.9 | 12.7 | 11.8 | 7.5 | 6.2 | 4.4 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|
|
| | 8.2 | 6.9 | 84.2 | 33.6 | -27.7 | 29.3 | 5.6 | -12.2 | -4.1 | 39.9 | 15.8 |
| 126 | 135 | 152 | 209 | 255 | 226 | 296 | 337 | 332 | 308 | 360 | 427 |
Operating Profit Operating ProfitCr |
| 11.2 | 12.3 | 7.3 | 30.8 | 36.9 | 22.4 | 21.6 | 15.4 | 5.0 | 8.2 | 23.4 | 21.5 |
Other Income Other IncomeCr | 0 | 3 | 3 | 9 | 12 | 12 | 8 | 8 | -20 | 4 | 12 | 19 |
Interest Expense Interest ExpenseCr | 5 | 6 | 10 | 14 | 21 | 19 | 18 | 17 | 21 | 17 | 14 | 12 |
Depreciation DepreciationCr | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 22 |
| 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 102 |
| 2 | 4 | 3 | 21 | 11 | -16 | 9 | 12 | 2 | 14 | 7 | 17 |
|
| | 184.4 | -403.4 | 766.3 | 115.0 | -49.5 | -28.5 | -64.6 | -452.8 | 54.8 | 418.2 | 11.2 |
| 0.7 | 1.8 | -5.0 | 18.1 | 29.2 | 20.4 | 11.3 | 3.8 | -15.2 | -7.2 | 16.3 | 15.6 |
| 0.2 | -0.4 | -4.2 | 3.1 | 13.6 | 20.6 | 15.8 | 5.3 | -17.7 | -5.4 | 26.4 | 29.8 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|
Equity Capital Equity CapitalCr | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 15 |
| 129 | 128 | 142 | 124 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 376 |
Current Liabilities Current LiabilitiesCr | 94 | 108 | 86 | 104 | 156 | 195 | 209 | 207 | 209 | 173 | 212 | 224 |
Non Current Liabilities Non Current LiabilitiesCr | 14 | 24 | 49 | 146 | 145 | 110 | 117 | 128 | 115 | 89 | 44 | 42 |
Total Liabilities Total LiabilitiesCr |
Current Assets Current AssetsCr | 91 | 95 | 104 | 182 | 296 | 284 | 310 | 314 | 253 | 242 | 335 | 336 |
Non Current Assets Non Current AssetsCr | 171 | 194 | 204 | 204 | 256 | 330 | 377 | 393 | 383 | 306 | 279 | 315 |
Total Assets Total AssetsCr |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Operating Cash Flow Operating Cash FlowCr | 15 | 7 | 2 | 59 | 90 | 34 | 63 | 43 | 116 | 105 | 41 |
Investing Cash Flow Investing Cash FlowCr | -18 | -15 | 7 | -101 | -97 | -44 | -42 | -26 | -55 | -16 | 0 |
Financing Cash Flow Financing Cash FlowCr | 1 | 10 | -12 | 89 | 12 | -47 | -1 | -22 | -41 | -91 | -51 |
|
Free Cash Flow Free Cash FlowCr | -20 | -23 | -17 | 42 | 55 | -34 | 7 | 6 | 76 | 86 | 38 |
| 1,579.9 | 240.1 | -23.2 | 108.1 | 76.6 | 57.9 | 147.2 | 288.4 | -218.5 | -438.8 | 53.5 |
CFO To EBITDA CFO To EBITDA% | 94.8 | 34.6 | 16.0 | 63.7 | 60.7 | 52.8 | 76.7 | 70.7 | 659.5 | 382.9 | 37.3 |
| Financial Year | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|
Valuation Ratios Valuation Ratios |
Market Cap Market CapitalizationCr | 136 | 160 | 176 | 654 | 755 | 626 | 737 | 605 | 315 | 446 | 805 |
Price To Earnings Price To Earnings | 595.0 | 0.0 | 0.0 | 19.4 | 6.4 | 10.3 | 15.9 | 38.5 | 0.0 | 0.0 | 10.4 |
Price To Sales Price To Sales | 1.0 | 1.0 | 1.1 | 2.2 | 1.9 | 2.1 | 1.9 | 1.5 | 0.9 | 1.3 | 1.7 |
Price To Book Price To Book | 1.0 | 1.2 | 1.2 | 5.3 | 3.0 | 2.0 | 2.0 | 1.6 | 1.0 | 1.5 | 2.2 |
| 9.4 | 10.8 | 21.0 | 8.5 | 5.8 | 12.3 | 11.3 | 13.2 | 27.0 | 19.1 | 7.7 |
Profitability Ratios Profitability Ratios |
| 55.6 | 58.3 | 58.4 | 73.6 | 77.1 | 72.9 | 64.4 | 61.6 | 56.1 | 61.2 | 68.6 |
| 11.2 | 12.3 | 7.3 | 30.8 | 36.9 | 22.4 | 21.6 | 15.4 | 5.0 | 8.2 | 23.4 |
| 0.7 | 1.8 | -5.0 | 18.1 | 29.2 | 20.4 | 11.3 | 3.8 | -15.2 | -7.2 | 16.3 |
| 4.6 | 7.4 | 2.0 | 30.7 | 33.5 | 12.1 | 11.7 | 7.2 | -5.7 | 1.7 | 20.4 |
| 0.7 | 2.1 | -5.7 | 43.4 | 47.1 | 19.2 | 11.8 | 4.0 | -16.9 | -8.3 | 21.1 |
| 0.4 | 0.9 | -2.7 | 14.2 | 21.4 | 9.7 | 6.2 | 2.1 | -8.3 | -4.4 | 12.4 |
Operational Ratios Operational Ratios |
Solvency Ratios Solvency Ratios |
Liquidity Ratios Liquidity Ratios |
### **Company Overview**
Fermenta Biotech Ltd. (FBL), formerly known as DIL Ltd., is a leading Indian multinational biotechnology company with a 74-year legacy (founded in 1951). Headquartered in Thane, Maharashtra, Fermenta operates at the intersection of **pharmaceuticals, nutrition, green chemistry, and environmental solutions**. The company is recognized globally as one of the **top three manufacturers of Vitamin D3 API**, and it is **India’s only manufacturer** of this critical nutrient.
Through a strategic transformation post the 2019 merger of DIL and Fermenta Biotech Limited, the company has evolved from a traditional API player into a science-driven, integrated nutrition and biotech solutions provider with a resilient, diversified business model.
---
### **Core Business Segments**
Fermenta operates across four primary verticals:
1. **Nutrition**
- Flagship product: **Vitamin D3** in multiple forms (crystalline, oil, cold water dispersible, spray-dried powder) for human and animal nutrition.
- Key innovations:
- **VITADEE™ Green**: World’s first **plant-based, vegan-compliant Vitamin D3** derived from phytosterols (patented Indian process), meeting multi-compendial standards and offering superior stability.
- **VITADEE™ 100 SD**: 100,000 IU/g **pharmaceutical-grade spray-dried Vitamin D3** with **CEP certification from EDQM**, enabling access to regulated European markets.
- Expanding portfolio: **Vitamin K1** (API USP and 5% spray-dried powder), **Fortified Rice Kernels (FRK)**, **Vitamin AD2** for oil fortification, and **custom nutritional premixes**.
- Leadership in **nutritional ingredient innovation** for preventive health, addressing immunity, bone health, and micronutrient deficiency.
2. **APIs & Intermediates**
- Manufactures **Phenyramidol HCl** (muscle relaxant) and **Activated Dimethicone Powder** (anti-flatulent API) for global pharmaceutical customers.
- R&D focus on **calcifediol**, **cholesterol synthesis**, and **niche APIs**.
- Innovations in green chemistry: **patented enzymatic synthesis of Molnupiravir**, an antiviral used in COVID-19 treatment.
3. **Green Chemistry & Enzymes**
- Pioneer in **immobilized enzyme technology** in India.
- Key enzyme products:
- **Fermase PA 850 & PS 250**: Penicillin G Amidase (PGA) enzymes for beta-lactam antibiotic synthesis (ampicillin, amoxicillin).
- **CAL B Lipase**: High-performance enzyme for green chemistry applications (chiral APIs, biofuels, oleochemicals, personal care).
- Enzymes used in **APIs, food, fragrances, biodiesel, and diagnostics**.
4. **Environmental Solutions**
- Provides **end-to-end biotech-based water and wastewater treatment** solutions.
- Services include **engineering, procurement, construction (EPC), STP/ETP operation**, and **maintenance contracts**.
- Proprietary product: **Fermsept®**, an eco-friendly microbial enhancer for efficient waste treatment.
- In October 2025, Fermenta transferred its environmental business to **Fermenta Environment Solutions Private Limited (FESPL)** via a slump sale to enable focused growth and operational excellence.
---
### **Manufacturing & R&D Infrastructure**
- **State-of-the-art manufacturing plants**:
- **Kullu, Himachal Pradesh**: Enzymes, Vitamin D3, APIs, and customized premixes.
- **Dahej, Gujarat**: Dedicated Vitamin D3 and fish oil cholesterol facility with **US FDA** and **EU GMP** certifications.
- **Tirupati, Andhra Pradesh**: Fortified Rice Kernels (FRK) manufacturing.
- **R&D Excellence Centre**: Located in **Thane, Maharashtra**, DSIR-approved with capabilities in:
- Multi-step organic synthesis
- Photochemistry and chromatography (API R&D)
- Fermentation, enzyme immobilization, and biocatalysis
- Formulation development for liquid and solid premixes
---
### **Global Presence & Revenue Mix (H1 FY26 / Q1 FY26)**
- **Serves over 400 customers** across **more than 60 countries**.
- **Revenue Distribution (excl. real estate, H1FY26)**:
- **India**: 40%
- **Europe**: 29%
- **North America**: 13%
- **Other Regions**: 18%
- **Trend**: Gradual internationalization, with India’s share declining from 43% (Q1 FY25) to 35% (Q1 FY26), while Europe and North America show positive momentum (+7pp and +3pp respectively).
---
### **Strategic Subsidiaries & Global Reach**
- **Fermenta USA LLC** (Texas):
- Acquired 52% stake in AGD Nutrition (2020), rebranded in 2020.
- Focus: **Human and animal nutrition distribution** in the largest nutraceutical market.
- Targeting major retailers (Walmart, CVS, Walgreens) with vitamin raw materials.
- **Fermenta Biotech GmbH** (Germany, Hamburg):
- Enables **local feed-grade Vitamin D3 powder production** via toll manufacturing.
- Strengthens European market access and offers “**Made in Europe**” advantages.
- **Distribution Partnerships**:
- **Kappa Bioscience**: Exclusive distributor for select **Vitamin K2** variants in India.
- **Atacama Bio (Chile)**: Exclusive distributor for **NatAxtin® (natural astaxanthin)** in human nutrition and aquaculture.
- **Golden Omega (Chile)**: Exclusive distributor of high-purity **Omega-3** products in Indian subcontinent.
---
### **Key Strategic Developments (2020–2025)**
- **2020**:
- Merger of DIL and Fermenta Biotech completed.
- Backward integration into **cholesterol production** (key Vitamin D3 raw material).
- **2021**:
- Acquisition of **AGD Nutrition LLC** (US) to strengthen North American presence.
- Commercial launch of **fish oil-derived cholesterol** for aquaculture.
- **2022**:
- Launch of **Vitamin AD2** for oil fortification.
- Feed-grade Vitamin D production begins in **Germany**.
- **2023–2024**:
- Commissioning of **FRK plant** (Tirupati) and **customized premix plant** (Kullu).
- Filing of **patents for VITADEE™ Green (plant-based D3)**.
- **2025**:
- **CEP certification** for spray-dried Vitamin D3 (Kullu).
- **Slump sale of environmental business** to FESPL to sharpen focus and drive specialization.
- Strategic shift toward **clean-label, value-added nutritional formats**.
---
### **Innovation & Intellectual Property**
- **Patents**:
- Proprietary process for **plant-based Vitamin D3 (VITADEE Green)**.
- Enzymatic synthesis of **Molnupiravir** and **Vitamin K1**.
- **Fermsept®** for bioremediation.
- **Green Chemistry Leadership**:
- Replaces hazardous processes with **enzymatic, sustainable routes**, reducing solvent use, energy, and waste.
- Positioned as a **strategic innovation partner**, not just a supplier.
---
### **Customer & Market Strategy**
- **Diversified Customer Base**:
- Serves **400+ customers** globally.
- **Low concentration risk**: Largest customer ≤ 9% revenue; top 5 account for 25%.
- **High-Value Clients**:
- 11 customers generate INR 5–15 crore annually.
- 2 customers contribute > INR 15 crore, indicating strong B2B client relationships.
- **Focus Areas**:
- **Preventive health**, **fortified foods**, **clean-label trends**, and **functional nutrition**.
- Expanding into **medical nutraceuticals** and **B2B nutrition ingredients**.
---
### **Financial Highlights (FY23)**
- **Consolidated Revenue**: ₹481 Crore.
- **Nutrition Business**: 73% (₹351 Crore), with **Human Vitamin D3** as top contributor (₹216 Crore).
- Real estate value unlocking and non-core assets contributed ₹67 Crore.
*(Note: Updated FY25 revenue mix reflects shift—India 40%, Europe 27%, North America 17%).*
---
### **Management & Leadership**
- **Managing Director**: Over 30 years in pharma, with deep expertise in APIs and R&D.
- **Executive Director (Anupama Datla Desai)**: Led transformation since 2006; oversees R&D, innovation, and strategic growth.
- Leadership emphasizes **science-driven, sustainable innovation** and **capital-efficient expansion**.
---
### **Investment Highlights**
- **Proven Innovator**: First-mover in vegan Vitamin D3, immobilized enzymes, and plant-based APIs.
- **Non-China Supply Chain**: Strategic advantage in a global market vulnerable to sourcing risks.
- **Regulatory Credibility**: Certified by **EDQM, US FDA, EU GMP, FSSC 22000, BRC, WHO-GMP, FAMI-QS**.
- **Sustainable & Scalable Model**: Backward integration, low customer concentration, diversified geographies.
- **High Growth Segments**: Nutraceuticals, food fortification, green chemistry, and sustainable nutrition.